Napoleone Ferrara - 18 Mar 2025 Form 4 Insider Report for Kalaris Therapeutics, Inc. (KLRS)

Reporting relationship: Director
Issuer ticker: KLRS
Reported as of: 18 Mar 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Mar 2025, 17:45:09 UTC
Next SEC filing: 11 Apr 2025
Source filing: View source filing
Reporting owner signature: /s/ Andrew Oxtoby, Attorney-in-Fact

Key filing fact

Napoleone Ferrara filed Form 4 for Kalaris Therapeutics, Inc. (KLRS) on 18 Mar 2025.

Key facts

This page summarizes Napoleone Ferrara's Form 4 filing for Kalaris Therapeutics, Inc. (KLRS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 18 Mar 2025, 17:45.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KLRS transaction

Common Stock

Award

Transaction value
Shares: +504,000
Change %
Price
Shares after: 504,000
Date: 18 Mar 2025
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Shares issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 7, 2024 (the "Merger Agreement"), by and among the Issuer, Aurora Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Issuer, and Kalaris Tx, Inc. (previously named Kalaris Therapeutics, Inc.), a Delaware corporation ("KTx"), in exchange for outstanding shares of KTx pursuant to the terms and conditions of the Merger Agreement (such transaction, the Merger).

Footnote F2

Pursuant to the terms of the Merger Agreement, as of the effective time of the Merger, each share of KTx common stock was converted into and became exchangeable for the right to receive 0.2016 shares of common stock of the Issuer.